Neumora Therapeutics, Inc.
NMRA
$2.29
$0.062.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.18M | 15.32M | 18.79M | 17.01M | 16.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.70M | 54.04M | 70.94M | 62.92M | 76.65M |
| Operating Income | -52.70M | -54.04M | -70.94M | -62.92M | -76.65M |
| Income Before Tax | -56.76M | -52.71M | -67.89M | -58.82M | -72.49M |
| Income Tax Expenses | -- | 25.00K | 105.00K | 0.00 | 53.00K |
| Earnings from Continuing Operations | -56.76M | -52.73M | -67.99M | -58.82M | -72.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.76M | -52.73M | -67.99M | -58.82M | -72.55M |
| EBIT | -52.70M | -54.04M | -70.94M | -62.92M | -76.65M |
| EBITDA | -52.68M | -54.02M | -70.78M | -62.77M | -76.49M |
| EPS Basic | -0.35 | -0.33 | -0.42 | -0.37 | -0.45 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.26 | -0.23 | -0.28 |
| EPS Diluted | -0.35 | -0.33 | -0.42 | -0.37 | -0.45 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.26 | -0.23 | -0.28 |
| Average Basic Shares Outstanding | 161.84M | 161.69M | 161.45M | 160.98M | 159.58M |
| Average Diluted Shares Outstanding | 161.84M | 161.69M | 161.45M | 160.98M | 159.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |